Clinical Trial Goal
To find out:
- The highest dose of LTZ-301 that's safe to give
- If LTZ-301 is safe and works well to treat NHL that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years old or older
- Have NHL that has relapsed or is refractory
- Do not have any of the following:
- Chronic lymphocytic leukemia
- Richter's transformation
- Do not have lymphoma in your brain or spinal cord
- Have not had allogeneic (cells from a donor) blood or marrow transplant (BMT)
- Have not had autologous (your own cells) BMT in the last 3 months
- Have not had CAR T cell therapy in the last 2 months
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
LTZ-301 is a bispecific myeloid engager antibody that targets CD79b on certain cells.
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
- LTZ-301 – Given as intravenous (IV) infusions. The dose you'll get depends on when you start the trial and how safe it has been
You may continue treatment for about 1 year. You'll have scans to see how well the treatment is working.
The Food and Drug Administration (FDA) has not yet approved LTZ-301.
Locations
City of HopeRECRUITING
Duarte, California
Elizabeth Budde, MD, 626-218-2405, ebudde@coh.org
Washington University School of MedicineRECRUITING
St Louis, Missouri
Anne Fischer, 314-362-3021, afischer@wustl.edu
Tennessee OncologyRECRUITING
Nashville, Tennessee
Michael Byrne, DO, 888-550-2835, mbyrne@tnonc.com
Sponsors
lead: LTZ Therapeutics, Inc.
